Amarin CEO: Consumers Have Heard About Omega-3 Heart Benefits 'Too Long'
As Amarin expects jump in Vascepa sales from potential label expansion allowing larger patient group, John Thero notes competitors fail to show broader cardiovascular risk reduction, but consumers still hear omega-3 supplements "might work."
You may also be interested in...
In Amarin’s “education process” about indication as an add-on to statin therapy to help cut CV risk in high-risk patients, it “will also be emphasizing how Vascepa is different from” Rx drugs fenofibrate and niacin “and omega-3 mixtures,” says CEO John Thero.
The court included its decision on Amarin’s ’s petition for a writ of certiorari among the single-line denials of nearly 200 appeals to consider decisions in civil litigation and convictions in criminal cases. However, Amarin still eyes curbing competition from omega-3 supplements.
In petition to Supreme Court, Amarin does not assert it makes any fair trade claim "that could be proved without establishing" an FDCA violation, nor does it dispute that its "claims are ultimately premised on allegations that the FDCA was violated," say DoJ solicitor general and ITC counsel.